Look back at pharma news in the week to January 15, 2021

17 January 2021

By Barbara Obstoj-Cardwell. Editor

Last week saw the third M&A deal this year, with Sanofi announcing it proposes to buy UK immuno-oncology focussed biotech firm Kymab in a deal worth up to $1.45 billion. US pharma major Eli Lilly pleased the Alzheimer’s community, coming up with encouraging Phase II results for its candidate donanemab. Also, Swiss pharma giant Novartis entered into a license deal with Sino-American firm BeiGene to expand its immune-oncology portfolio.

Sanofi makes a pre-JP Morgan splash with Kymab

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK